EGFR and lung adenocarcinoma: We previously reported that the mTOR pathway not only serves as a predictive marker for sensitivity to the combination of the EGFR‐TKI inhibitor WZ4002 and trametinib, but also is involved in acquired resistance to this combination treatment in EGFR mutant lung adenocarcinoma (Tricker et al., 2015).